Neoadjuvant chemotherapy for early breast cancer - Author's reply

Affiliations

¹ EBCTCG Secretariat, Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, Oxford OX3 7LF, UK. Electronic address: bc.overview@ndph.ox.ac.uk.
² EBCTCG Secretariat, Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, Oxford OX3 7LF, UK.

Comment

Paul McGale et al. Lancet Oncol. 2018 Mar.

. 2018 Mar;19(3):e130.

doi: 10.1016/S1470-2045(18)30120-7.

¹ EBCTCG Secretariat, Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, Oxford OX3 7LF, UK. Electronic address: bc.overview@ndph.ox.ac.uk.
² EBCTCG Secretariat, Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, Oxford OX3 7LF, UK.

No abstract available

Comment on

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet Oncol. 2018 Jan;19(1):27-39. doi: 10.1016/S1470-2045(17)30777-5. Epub 2017 Dec 11. Lancet Oncol. 2018. PMID: 29242041 Free PMC article. Review.
Neoadjuvant chemotherapy for early breast cancer.
Charalampoudis P, Karakatsanis A. Charalampoudis P, et al. Lancet Oncol. 2018 Mar;19(3):e128. doi: 10.1016/S1470-2045(18)30115-3. Lancet Oncol. 2018. PMID: 29508753 No abstract available.
Neoadjuvant chemotherapy for early breast cancer.
Krug D, Loibl S. Krug D, et al. Lancet Oncol. 2018 Mar;19(3):e129. doi: 10.1016/S1470-2045(18)30118-9. Lancet Oncol. 2018. PMID: 29508754 No abstract available.